H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets

MannKind Corporation (NASDAQ:MNKD) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, H.C. Wainwright increased its price target on MannKind Corporation (NASDAQ:MNKD) from $8 to $10 and kept its Buy rating on the stock.

The research firm noted that MannKind Corporation’s (NASDAQ:MNKD) first-quarter results came in below expectations, but this does not affect the core thesis. H.C. Wainwright told investors in a research note that the core thesis is increasingly focused on the durability and upside potential of the company’s royalty and collaboration revenue streams. The firm also pointed to potential pipeline upside as a reason for the higher price target.

H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets

On the same day, Wells Fargo also increased its price target on MannKind Corporation (NASDAQ:MNKD) from $8 to $10 and maintained its Overweight rating on the stock.

Wells Fargo highlighted the company’s involvement with Ralinepag DPI and noted upcoming PDUFA decisions for Afrezza and Furoscix. Wells Fargo said these developments could provide several paths for revenue growth.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapeutic products and devices for those living with endocrine and orphan lung diseases.

While we acknowledge the risk and potential of MNKD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MNKD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Mid-Cap Stocks That Are On Fire Right Now and 10 Best American Tech Stocks to Buy.

Disclosure: None.  Follow Insider Monkey on Google News.